Writing and erasing ceramides to alter liver disease

[1]  P. Zhang,et al.  m^6A modification-tuned sphingolipid metabolism regulates postnatal liver development in male mice , 2023, Nature Metabolism.

[2]  Yan Xu,et al.  Mettl3-mediated mRNA m6A modification controls postnatal liver development by modulating the transcription factor Hnf4a , 2022, Nature Communications.

[3]  Liwei Xie,et al.  The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression , 2021, Nature Communications.

[4]  Chuan He,et al.  m6A RNA methylation: from mechanisms to therapeutic potential , 2021, The EMBO journal.

[5]  S. Summers,et al.  Ceramides in Metabolism: Key Lipotoxic Players. , 2020, Annual review of physiology.

[6]  R. Laaksonen,et al.  Ceramides and Ceramide Scores: Clinical Applications for Cardiometabolic Risk Stratification , 2020, Frontiers in Endocrinology.

[7]  S. Summers,et al.  Metabolic Messengers: ceramides , 2019, Nature Metabolism.

[8]  James E. Cox,et al.  Targeting a ceramide double bond improves insulin resistance and hepatic steatosis , 2019, Science.

[9]  T. Langer,et al.  CerS6-Derived Sphingolipids Interact with Mff and Promote Mitochondrial Fragmentation in Obesity , 2019, Cell.

[10]  S. Summers,et al.  CerS2 haploinsufficiency inhibits β-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. , 2014, Cell metabolism.

[11]  Matthias Blüher,et al.  Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. , 2014, Cell metabolism.

[12]  Chengqi Yi,et al.  N6-Methyladenosine in Nuclear RNA is a Major Substrate of the Obesity-Associated FTO , 2011, Nature chemical biology.